Q-omics provides the consensus-scored ZIM3 profile across patient tissues and cancer cell-line models. ZIM3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, ZIM3 is differentially expressed in 6, with the highest sampling consensus in KICH. Additionally, ZIM3 RNA expression shows 6,459 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CESC, KICH, and STAD as cancer lineages where ZIM3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZIM3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZIM3 survival associations across molecular data types. ZIM3 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZIM3 RNA expression–survival associations across cancer types. High ZIM3 expression shows unfavorable associations in SKCM, MESO, UCEC and ACC, but favorable associations in CESC and CHOL. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for ZIM3 RNA expression.
This table summarizes ZIM3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for ZIM3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZIM3 shows lower tumor expression in KICH and KIRC and higher tumor expression in HNSC, PRAD, LUSC and LIHC. The KICH box plot shows higher ZIM3 RNA expression in normal versus tumor tissue (log2 FC = −0.015, t-test p = .008).
This table shows molecular features associated with ZIM3 in patient tissues and cancer cell lines. In patient samples, ZIM3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ZIM3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
